Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMartinello, M.en
dc.contributor.authorHellard, M.en
dc.contributor.authorShaw, D.en
dc.contributor.authorPetoumenos, K.en
dc.contributor.authorApplegate, T.en
dc.contributor.authorGrebely, J.en
dc.contributor.authorYeung, B.en
dc.contributor.authorMaire, L.en
dc.contributor.authorIser, D.en
dc.contributor.authorLloyd, A.en
dc.contributor.authorThompson, A.en
dc.contributor.authorSasadeusz, J.en
dc.contributor.authorHaber, P.en
dc.contributor.authorDore, G.en
dc.contributor.authorMatthews, G.en
dc.identifier.citationAntiviral Therapy, 2016; 21(5):425-434en
dc.description.abstractIndividuals with recent HCV infection may benefit from shortened duration therapy. These studies evaluated the efficacy and safety of response-guided regimens with pegylated interferon-α2a and ribavirin for people with recent HCV infection.Participants with recent hepatitis C (duration of infection ≤18 months) enrolled in the ATAHC II (pegylated interferon-α2a ± ribavirin) and DARE-C I (pegylated interferon-α2a, ribavirin and telaprevir) studies were included for analysis. Treatment duration was response-guided (ATAHC II: 8, 16, 24 or 48 weeks; DARE-C I: 8, 12 or 24 weeks) and dependent on time to first undetectable HCV RNA using Roche Taqman HCV RNA testing. The primary efficacy end point was sustained virological response at 12 weeks (SVR12) by intention-to-treat. Logistic regression analyses were used to identify predictors of SVR.A total of 82 participants (62% HIV-positive) were enrolled in ATAHC II (treated, n=52) and 14 (79% HIV-positive) in DARE-C I. The predominant modes of HCV acquisition were injecting drug use (ATAHC II 55%, DARE-C I 36%) and sexual intercourse with a partner of the same sex (ATAHC II 39%, DARE-C I 64%). SVR12 was 71% in both ATAHC II (37/52) and DARE-C I (10/14) with 56% in ATAHC II receiving shortened therapy (8 or 16 weeks). SVR was associated with a rapid virological response (odds ratio 10.80; P=0.001).The majority of participants were able to receive short duration response-guided therapy with pegylated interferon-α2a and ribavirin. Response-guided therapy for recent hepatitis C infection could be considered in the absence of available interferon-free therapies. registry (ATAHC II: NCT01336010; DARE-C I: NCT01743521).en
dc.description.statementofresponsibilityMarianne Martinello, Margaret Hellard, David Shaw, Kathy Petoumenos, Tanya Applegate, Jason Grebely, Barbara Yeung, Laurence Maire, David Iser, Andrew Lloyd, Alexander Thompson, Joe Sasadeusz, Paul Haber, Gregory J Dore, Gail V Matthewsen
dc.publisherInternational Medical Pressen
dc.rightsCopyright (c) 2016 International Medical Press, all rights reserved.en
dc.subjectHumans; Hepatitis C; Hepatitis C, Chronic; Polyethylene Glycols; Oligopeptides; Interferon-alpha; Recombinant Proteins; RNA, Viral; Ribavirin; Antiviral Agents; Treatment Failure; Drug Therapy, Combination; Drug Administration Schedule; Prospective Studies; Time Factors; Adult; Middle Aged; Female; Male; Medication Adherenceen
dc.titleShort duration response-guided treatment is effective for most individuals with recent hepatitis C infection: The ATAHC II and DARE-C i studiesen
dc.typeJournal articleen
pubs.library.collectionMedicine publicationsen
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.